X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with Unichem Lab - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs UNICHEM LAB - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES UNICHEM LAB DIVIS LABORATORIES/
UNICHEM LAB
 
P/E (TTM) x 32.4 -278.7 - View Chart
P/BV x 5.3 2.1 255.7% View Chart
Dividend Yield % 0.9 1.2 75.7%  

Financials

 DIVIS LABORATORIES   UNICHEM LAB
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-17
UNICHEM LAB
Mar-17
DIVIS LABORATORIES/
UNICHEM LAB
5-Yr Chart
Click to enlarge
High Rs1,222320 382.0%   
Low Rs784221 354.8%   
Sales per share (Unadj.) Rs153.1167.2 91.6%  
Earnings per share (Unadj.) Rs39.912.0 334.0%  
Cash flow per share (Unadj.) Rs44.616.9 263.4%  
Dividends per share (Unadj.) Rs10.003.00 333.3%  
Dividend yield (eoy) %1.01.1 89.9%  
Book value per share (Unadj.) Rs201.8117.0 172.4%  
Shares outstanding (eoy) m265.4790.88 292.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.61.6 405.0%   
Avg P/E ratio x25.122.6 111.0%  
P/CF ratio (eoy) x22.516.0 140.8%  
Price / Book Value ratio x5.02.3 215.1%  
Dividend payout %25.025.1 99.8%   
Avg Mkt Cap Rs m266,26624,578 1,083.3%   
No. of employees `0009.75.2 187.6%   
Total wages/salary Rs m4,6872,487 188.4%   
Avg. sales/employee Rs Th4,175.02,928.3 142.6%   
Avg. wages/employee Rs Th481.5479.4 100.4%   
Avg. net profit/employee Rs Th1,089.3209.4 520.1%   
INCOME DATA
Net Sales Rs m40,64315,195 267.5%  
Other income Rs m749110 679.6%   
Total revenues Rs m41,39215,305 270.4%   
Gross profit Rs m14,4601,788 808.8%  
Depreciation Rs m1,233452 273.0%   
Interest Rs m2334 67.1%   
Profit before tax Rs m13,9531,413 987.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,349326 1,028.0%   
Profit after tax Rs m10,6041,087 975.7%  
Gross profit margin %35.611.8 302.4%  
Effective tax rate %24.023.1 104.1%   
Net profit margin %26.17.2 364.8%  
BALANCE SHEET DATA
Current assets Rs m40,1056,426 624.1%   
Current liabilities Rs m6,5953,917 168.3%   
Net working cap to sales %82.516.5 499.4%  
Current ratio x6.11.6 370.7%  
Inventory Days Days11968 175.2%  
Debtors Days Days8177 104.8%  
Net fixed assets Rs m19,9957,410 269.8%   
Share capital Rs m531182 292.0%   
"Free" reserves Rs m53,04310,454 507.4%   
Net worth Rs m53,57410,636 503.7%   
Long term debt Rs m04 0.0%   
Total assets Rs m61,58515,258 403.6%  
Interest coverage x618.442.9 1,440.9%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.71.0 66.3%   
Return on assets %17.37.3 235.0%  
Return on equity %19.810.2 193.7%  
Return on capital %26.113.6 191.9%  
Exports to sales %024.1 0.0%   
Imports to sales %25.24.9 510.3%   
Exports (fob) Rs mNA3,666 0.0%   
Imports (cif) Rs m10,259752 1,365.0%   
Fx inflow Rs m35,3845,298 667.8%   
Fx outflow Rs m10,3990-   
Net fx Rs m24,9855,298 471.6%   
CASH FLOW
From Operations Rs m11,493683 1,681.8%  
From Investments Rs m-11,372-1,316 864.4%  
From Financial Activity Rs m-93592 -15.7%  
Net Cashflow Rs m28-40 -71.2%  

Share Holding

Indian Promoters % 52.0 50.1 103.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 15.1 78.1%  
FIIs % 19.0 3.0 633.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 31.7 54.3%  
Shareholders   31,796 20,176 157.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   VENUS REMEDIES  ORCHID PHARMA LTD  SANOFI INDIA  TTK HEALTHCARE  SHASUN PHARMA  

Compare DIVIS LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

OPEC Meeting; Upcoming IPOs; IDBI Bank, Emami among Top Stocks in Action Today(Pre-Open)

Indian share markets edged up on Friday with Nifty 50 closing above 10,800-levels, even as broader global markets remained weak.

Related Views on News

UNICHEM LAB Announces Quarterly Results (4QFY18); Net Profit Down 91.1%

Jun 14, 2018 | Updated on Jun 14, 2018

For the quarter ended March 2018, UNICHEM LAB has posted a net profit of Rs 28 m (down 91.1% YoY). Sales on the other hand came in at Rs 2 bn (down 40.4% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY18); Net Profit Up 0.9%

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 0.9% YoY). Sales on the other hand came in at Rs 11 bn (up 2.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

This Behaviour is Injurious to Wealth Building(Sector Info)

Jun 13, 2018

Blindly following the herd can be the biggest wealth destroyer.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Jun 25, 2018 09:29 AM

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 8-QTR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS